Dermata Therapeutics (DRMA) Competitors $1.08 +0.03 (+2.86%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends DRMA vs. GNPX, BCLI, ENSC, BFRI, AYTU, ADXN, VIRX, CDT, OBSV, and CEROShould you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include Genprex (GNPX), Brainstorm Cell Therapeutics (BCLI), Ensysce Biosciences (ENSC), Biofrontera (BFRI), Aytu BioPharma (AYTU), Addex Therapeutics (ADXN), Viracta Therapeutics (VIRX), Conduit Pharmaceuticals (CDT), ObsEva (OBSV), and CERo Therapeutics (CERO). These companies are all part of the "pharmaceutical products" industry. Dermata Therapeutics vs. Genprex Brainstorm Cell Therapeutics Ensysce Biosciences Biofrontera Aytu BioPharma Addex Therapeutics Viracta Therapeutics Conduit Pharmaceuticals ObsEva CERo Therapeutics Dermata Therapeutics (NASDAQ:DRMA) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, community ranking, dividends, valuation, institutional ownership and earnings. Which has more risk and volatility, DRMA or GNPX? Dermata Therapeutics has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Genprex has a beta of -1.38, suggesting that its share price is 238% less volatile than the S&P 500. Is DRMA or GNPX more profitable? Dermata Therapeutics' return on equity of -247.39% beat Genprex's return on equity.Company Net Margins Return on Equity Return on Assets Dermata TherapeuticsN/A -247.39% -179.72% Genprex N/A -409.48%-269.17% Does the MarketBeat Community prefer DRMA or GNPX? Genprex received 194 more outperform votes than Dermata Therapeutics when rated by MarketBeat users. Likewise, 65.25% of users gave Genprex an outperform vote while only 50.00% of users gave Dermata Therapeutics an outperform vote. CompanyUnderperformOutperformDermata TherapeuticsOutperform Votes550.00% Underperform Votes550.00% GenprexOutperform Votes19965.25% Underperform Votes10634.75% Do insiders and institutionals hold more shares of DRMA or GNPX? 8.7% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 9.4% of Dermata Therapeutics shares are owned by insiders. Comparatively, 8.5% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts prefer DRMA or GNPX? Dermata Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 455.56%. Genprex has a consensus target price of $10.00, indicating a potential upside of 998.90%. Given Genprex's higher probable upside, analysts plainly believe Genprex is more favorable than Dermata Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Genprex 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, DRMA or GNPX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDermata TherapeuticsN/AN/A-$7.80M-$16.41-0.07GenprexN/AN/A-$30.86MN/AN/A Does the media refer more to DRMA or GNPX? In the previous week, Genprex had 1 more articles in the media than Dermata Therapeutics. MarketBeat recorded 2 mentions for Genprex and 1 mentions for Dermata Therapeutics. Dermata Therapeutics' average media sentiment score of 0.48 beat Genprex's score of 0.47 indicating that Dermata Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dermata Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genprex 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryDermata Therapeutics beats Genprex on 6 of the 11 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRMA vs. The Competition Export to ExcelMetricDermata TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.20M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.0710.5990.0517.20Price / SalesN/A196.061,117.09117.04Price / CashN/A57.1643.1037.85Price / Book0.045.094.784.78Net Income-$7.80M$151.83M$120.31M$225.60M7 Day Performance-0.92%-2.14%-1.92%-1.23%1 Month Performance-5.26%-4.56%13.65%0.46%1 Year Performance-88.40%8.87%28.34%15.24% Dermata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRMADermata Therapeutics2.5691 of 5 stars$1.08+2.9%$6.00+455.6%-88.2%$2.20MN/A-0.078GNPXGenprex3.9233 of 5 stars$1.05-9.5%$10.00+852.4%-89.1%$8.93MN/A0.0020Gap UpBCLIBrainstorm Cell Therapeutics3.9873 of 5 stars$1.54+6.0%$30.00+1,852.7%-21.2%$8.76MN/A-0.3040Gap UpENSCEnsysce Biosciences0.0873 of 5 stars$6.62+17.8%N/A-49.1%$8.65M$2.23M-0.2010BFRIBiofrontera1.4519 of 5 stars$1.11+4.7%$7.00+530.6%-69.7%$8.60M$35.36M-0.4770Gap DownAYTUAytu BioPharma0.8898 of 5 stars$1.39-3.5%N/A-52.9%$8.55M$81M-1.17160Positive NewsADXNAddex Therapeutics2.7065 of 5 stars$8.02+0.3%$30.00+274.1%+39.1%$8.50M$556,045.00-23.5330Gap DownVIRXViracta Therapeutics2.5296 of 5 stars$0.20+0.6%$5.00+2,351.0%-56.7%$8.11MN/A-0.1820Gap DownCDTConduit PharmaceuticalsN/A$0.08-4.8%N/A-98.5%$7.98MN/A0.003OBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150Analyst ForecastNews CoverageCEROCERo TherapeuticsN/A$0.05-8.1%N/AN/A$7.83MN/A0.008 Related Companies and Tools Related Companies GNPX Competitors BCLI Competitors ENSC Competitors BFRI Competitors AYTU Competitors ADXN Competitors VIRX Competitors CDT Competitors OBSV Competitors CERO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DRMA) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
